Citigroup’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-348,421
| Closed | -$77M | – | 5986 |
|
|
2025
Q4 | $77M | Buy |
348,421
+346,474
| +17,795% | +$56M | 0.03% | 463 |
|
|
2025
Q3 | $186K | Sell |
1,947
-3,696
| -65% | -$236K | ﹤0.01% | 4018 |
|
|
2025
Q2 | $275K | Buy |
5,643
+5,066
| +878% | +$122K | ﹤0.01% | 3916 |
|
|
2025
Q1 | $12.4K | Sell |
577
-7,007
| -92% | -$156K | ﹤0.01% | 5159 |
|
|
2024
Q4 | $204K | Buy |
+7,584
| New | +$123K | ﹤0.01% | 4401 |
|
|
2021
Q3 | – | Sell |
-200
| Closed | -$8K | – | 5805 |
|
|
2021
Q2 | $8K | Sell |
200
-129
| -39% | -$5.46K | ﹤0.01% | 5733 |
|
|
2021
Q1 | $18K | Sell |
329
-200
| -38% | -$9.88K | ﹤0.01% | 5305 |
|
|
2020
Q4 | $21K | Buy |
529
+244
| +86% | +$12.1K | ﹤0.01% | 6608 |
|
|
2020
Q3 | $16K | Sell |
285
-137
| -32% | -$9.68K | ﹤0.01% | 6319 |
|
|
2020
Q2 | $31K | Buy |
422
+111
| +36% | +$7.19K | ﹤0.01% | 6289 |
|
|
2020
Q1 | $15K | Buy |
311
+111
| +56% | +$6.65K | ﹤0.01% | 6849 |
|
|
2019
Q4 | $15K | Hold |
200
| – | – | ﹤0.01% | 7049 |
|
|
2019
Q3 | $8K | Hold |
200
| – | – | ﹤0.01% | 7165 |
|
|
2019
Q2 | $7K | Hold |
200
| – | – | ﹤0.01% | 7385 |
|
|
2019
Q1 | $11K | Buy |
+200
| New | +$11K | ﹤0.01% | 7206 |
|
|
2017
Q2 | – | Sell |
-8
| Closed | -$1K | – | 7343 |
|
|
2017
Q1 | $1K | Sell |
8
-105
| -93% | -$18.4K | ﹤0.01% | 7068 |
|
|
2016
Q4 | $23K | Buy |
113
+53
| +88% | +$11K | ﹤0.01% | 6473 |
|
|
2016
Q3 | $14K | Hold |
60
| – | – | ﹤0.01% | 6380 |
|
|
2016
Q2 | $12K | Sell |
60
-201
| -77% | -$48.6K | ﹤0.01% | 6443 |
|
|
2016
Q1 | $67K | Buy |
261
+188
| +258% | +$43.3K | ﹤0.01% | 5936 |
|
|
2015
Q4 | $25K | Buy |
+73
| New | +$21.9K | ﹤0.01% | 6368 |
|
|
2015
Q3 | – | Sell |
-6
| Closed | -$2K | – | 7391 |
|
|
2015
Q2 | $2K | Buy |
+6
| New | +$1.84K | ﹤0.01% | 7110 |
|
Citigroup's CDTX Position: Q1 2026 in Review
Citigroup sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 348,421 shares — an estimated $77M sold.
Citigroup first reported a position in CDTX in Q2 2015 and held it in 22 quarters. The position peaked at $77M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Citigroup reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citigroup sold 348,421 Cidara Therapeutics shares in Q1 2026, an estimated $77M.
- Citigroup first reported a position in Cidara Therapeutics in Q2 2015 and held it in 22 quarters.
- Citigroup's Cidara Therapeutics position peaked at $77M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.